Literature DB >> 7908404

Negative antagonists promote an inactive conformation of the beta 2-adrenergic receptor.

P Samama1, G Pei, T Costa, S Cotecchia, R J Lefkowitz.   

Abstract

The beta 2-adrenergic receptor undergoes isomerization between an inactive conformation (R) and an active conformation (R*). The formation of the active conformation of the receptor molecule can be promoted by adrenergic agonists or by mutations in the third cytoplasmic domain that constitutively activate the receptor. Here we show that, of several beta-adrenergic receptor-blocking drugs tested, only two, ICI 118551 and betaxolol, inhibit the basal signaling activity of the beta 2-adrenergic receptor, thus acting as negative antagonists. We document the molecular properties of the more efficacious ICI 118551; (i) it shows higher affinity for the inactive form of the receptor and (ii) it inhibits the spontaneous formation of a beta-adrenergic receptor kinase substrate by the receptor. These properties are opposite those of adrenergic agonists, indicating that, in a fashion reciprocal to that of agonists, negative antagonists promote the formation of an inactive conformation of the receptor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7908404

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  43 in total

1.  Detection of receptor ligands by monitoring selective stabilization of a Renilla luciferase-tagged, constitutively active mutant, G-protein-coupled receptor.

Authors:  D Ramsay; N Bevan; S Rees; G Milligan
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Non-competitive antagonism of beta(2)-agonist-mediated cyclic AMP accumulation by ICI 118551 in BC3H1 cells endogenously expressing constitutively active beta(2)-adrenoceptors.

Authors:  H E Hopkinson; M L Latif; S J Hill
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

3.  Development and characterization of pepducins as Gs-biased allosteric agonists.

Authors:  Richard Carr; Yang Du; Julie Quoyer; Reynold A Panettieri; Jay M Janz; Michel Bouvier; Brian K Kobilka; Jeffrey L Benovic
Journal:  J Biol Chem       Date:  2014-11-13       Impact factor: 5.157

4.  Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.

Authors:  C Hoffmann; M R Leitz; S Oberdorf-Maass; M J Lohse; K-N Klotz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-01-17       Impact factor: 3.000

5.  Inverse agonism of histamine H2 antagonist accounts for upregulation of spontaneously active histamine H2 receptors.

Authors:  M J Smit; R Leurs; A E Alewijnse; J Blauw; G P Van Nieuw Amerongen; Y Van De Vrede; E Roovers; H Timmerman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

Review 6.  Oligomerization of G protein-coupled receptors: past, present, and future.

Authors:  Paul S-H Park; Slawomir Filipek; James W Wells; Krzysztof Palczewski
Journal:  Biochemistry       Date:  2004-12-21       Impact factor: 3.162

7.  The origins of diversity and specificity in g protein-coupled receptor signaling.

Authors:  Stuart Maudsley; Bronwen Martin; Louis M Luttrell
Journal:  J Pharmacol Exp Ther       Date:  2005-04-01       Impact factor: 4.030

8.  β-arrestin-biased signaling through the β2-adrenergic receptor promotes cardiomyocyte contraction.

Authors:  Richard Carr; Justin Schilling; Jianliang Song; Rhonda L Carter; Yang Du; Sungsoo M Yoo; Christopher J Traynham; Walter J Koch; Joseph Y Cheung; Douglas G Tilley; Jeffrey L Benovic
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-27       Impact factor: 11.205

9.  Restricting mobility of Gsalpha relative to the beta2-adrenoceptor enhances adenylate cyclase activity by reducing Gsalpha GTPase activity.

Authors:  K Wenzel-Seifert; T W Lee; R Seifert; B K Kobilka
Journal:  Biochem J       Date:  1998-09-15       Impact factor: 3.857

10.  Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor.

Authors:  Elliott J Sally; Heng Xu; Christina M Dersch; Ling-Wei Hsin; Li-Te Chang; Thomas E Prisinzano; Denise S Simpson; Denise Giuvelis; Kenner C Rice; Arthur E Jacobson; Kejun Cheng; Edward J Bilsky; Richard B Rothman
Journal:  Synapse       Date:  2010-04       Impact factor: 2.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.